At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
VGX-410 (Mifepristone) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled, Dose Escalating, Phase II Trial of the Anti -HIV-Activity and Safety of VGX-410 (Mifepristone) in HIV-1 Infected Subjects
In Brief
A Phase 2 clinical trial evaluating VGX-410 (Mifepristone) and Placebo for VGX-410 (Mifepristone) for HIV Infections. Completed, enrolled 19 participants across 3 sites.
Detailed Summary
The objective of the study is to determine whether mifepristone (VGX-410) has anti-HIV-1 activity at doses of either 300 mg or 600 mg per day after oral administration for 14 days at each dose level.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedJul 2006
Primary CompletionJun 2007
Study CompletionNov 2007
TodayJul 2026
First PostedJul 17, 2006
Enrollment StartJul 1, 2006
Primary CompletionJun 1, 2007
Study CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 20.0 years ago
Interventions
VGX-410 (Mifepristone)drug
Placebo for VGX-410 (Mifepristone)drug